Showing posts with label Prostate. Show all posts
Showing posts with label Prostate. Show all posts

Monday, March 29, 2010

active surveillance for large numbers of prostate cancer patients

Moral of the story: With prostate screening methods being pretty crummy, people are finally starting to realize that low grade prostate cancer might be better treated (at least at first) simply with a watch and wait protocol. Biopsy and surgery have risks, which may be able to be postponed indefinitely.

Source: AMA Morning Rounds 3/29/2010

Major medical organization endorses active surveillance for large numbers of prostate cancer patients.


The Chicago Tribune (3/28, Graham) reported that "for the first time," active surveillance is "being endorsed for large numbers of men by a major medical organization: the National Comprehensive Cancer Network, an alliance of 21 leading cancer centers across the US." According to "new guidelines," the approach is recommended "for men deemed to have 'very low risk' prostate cancer and a life expectancy of less than 20 years," as well as for those men whose "prostate cancer is considered 'low risk' and" have a "life expectancy" of "less than 10 years." In other words, "almost 40 percent of the 192,000 men diagnosed with prostate cancer each year could qualify for active surveillance under those standards, said Dr. James Mohler," part of the "committee that prepared the guidelines."
        Researchers in Illinois conducting active surveillance studies. The Chicago Tribune (3/28, Graham) reported that last year, NorthShore University Health System began "recruiting men who are at least 60 years old with low-grade prostate cancer (Gleason score of 6 or less) and relatively low PSA scores (less than 10)" to find out which patients "can be managed safely with active surveillance." Adhering to "a slightly different protocol," University of Chicago researchers are also "tracking about 50 men with low-grade, low-risk prostate cancers." Meanwhile, a third trial, in which University of Toronto researchers "examined 453 men undergoing active surveillance over a period of up to 13 years," revealed that "men's risk of dying from prostate cancer during the study was one percent, while their risk of dying from another condition was 16 times as high," according to results "presented last year at meetings of the American Society of Clinical Oncology."

Sunday, November 29, 2009

Keeping cholesterol in check may reduce prostate cancer risk, studies suggest.

Moral of the story: So many reasons to keep your heart healthy. Cholesterol is now linked to prostate cancer.

Source: AMA Morning Rounds 11/4/09

Keeping cholesterol in check may reduce prostate cancer risk, studies suggest.

The AP (11/4, Marchione) reports, "Men may protect more than their hearts if they keep cholesterol in line: Their chances of getting aggressive prostate cancer may be lower." Scientists at two institutions detailed the research that led them to that conclusion in Cancer Epidemiology Biomarkers & Prevention. Even though the papers "are not definitive and have some weaknesses," they do "fit with plenty of other science suggesting that limiting fats in the bloodstream can lessen cancer risk."

HealthDay (11/3, Edelson) reported that NCI investigators reviewed "data from a study that has followed more than 29,000 Finnish men for 18 years," finding that "cholesterol levels below the generally recommended 200 milligrams per deciliter were associated with an 18 percent higher overall risk of cancer."

Wednesday, March 18, 2009

Prostate Cancer Test Found to Save Few Lives

Moral of the story: Finally there is data to back up the uselessness of the PSA test. Do not bother with this! They haven't used it for years in Europe.

Prostate Cancer Test Found to Save Few Lives

By GINA KOLATA
Published: March 18, 2009- NYTimes

The PSA blood test — the screening test for prostate cancer — saves few if any lives and exposes large numbers of men to risky and unnecessary treatment, two large and rigorous studies have found.

The findings raise new questions about the rapid and widespread adoption of the test, which measures a protein released by prostate cells. It was introduced in 1987 and quickly became a routine part of preventive health care. Experts debated its value, basing their views on data that often involved statistical modeling and inferences.

Now, with the new data, cancer experts said men should carefully consider the test’s risks and benefits before deciding to be screened. Some may decide not to be screened at all.

The studies, said Dr. Otis Brawley, the chief medical officer at the American Cancer Society, are “some of the most important studies in the history of men’s health.”

For years, the cancer society has urged men to be informed before deciding to have a PSA test. “Now we actually have something to inform them with,” he said. “We’ve got numbers.”

Dr. H. Gilbert Welch, a professor of medicine at Dartmouth who studies cancer screening, also welcomed the new data. “We’ve been waiting years for this,” he said. “It’s a shame we didn’t have it 20 years ago.”

Both reports were published online on Wednesday by The New England Journal of Medicine. One involved 182,000 men in seven European countries; the other, by the National Cancer Institute, involved nearly 77,000 men at 10 medical centers in the United States.

In both, participants were randomly assigned to be screened — or not — with the PSA test, whose initials stand for prostate-specific antigen. In each study, the two groups were followed for more than a decade while researchers counted deaths from prostate cancer, asking whether screening made a difference.

The European data involved a consortium of studies with different designs. Taken together, the studies found that screening was associated with a 20 percent relative reduction in the prostate cancer death rate. But the number of lives saved was small — seven fewer prostate cancer deaths for every 10,000 men screened and followed for nine years.

The American study, which had a single design, found no reduction in deaths from prostate cancer after most of the men had been followed for 10 years. Every man has been followed for at least seven years, said Dr. Barnett Kramer, a study co-author at the National Institutes of Health. By seven years, the death rate was 13 percent lower for the unscreened group.

The European study saw no benefit of screening in the first seven years of follow-up.

The reason screening saved so few lives, cancer experts say, is that prostate cancers often grow very slowly, if at all, and most never endanger a man if left alone. But when doctors find an early-stage prostate tumor, they cannot tell with confidence whether it will be dangerous so they usually treat all early cancers as if they were life-threatening.

As a result, the majority of men, whose early-stage cancers would not harm them, suffer serious effects of cancer therapy but get no benefit. Others, with very aggressive tumors, may not be helped by screening because their cancer has spread by the time it is detected.

Prostate cancer is not the only one that is hard to stop with screening. If the European study is correct, mammography has about the same benefit as the PSA test, said Dr. Michael B. Barry, a prostate cancer researcher at Massachusetts General Hospital who wrote an editorial accompanying the papers. But prostate cancers often are less dangerous than breast cancers, so screening and subsequent therapy can result in more harm.

In the European study, 48 men were told they had prostate cancer, and needlessly treated for it, for every man whose death was prevented. With mammography, about 10 women receive a diagnosis and needless treatment for breast cancer to prevent one death.

Dr. Peter B. Bach, a physician and epidemiologist at Memorial Sloan-Kettering Cancer Center, says one way to think of the data is to suppose he has a PSA test today. It leads to a biopsy that reveals he has prostate cancer, and he is treated for it. There is a one in 50 chance that, in 2019 or later, he will be spared death from a cancer that would otherwise have killed him. And there is a 49 in 50 chance that he will have been treated unnecessarily for a cancer that was never a threat to his life or health.

Prostate cancer treatment can result in impotence and incontinence when surgery is used to destroy the prostate, and painful defecation or chronic diarrhea when the treatment is radiation.

When the American and European studies began, in the early 1990s, PSA testing was well under way in the United States, and many expected that the screening test would make the prostate cancer death rate plummet by 50 percent or more. Dr. Brawley was at the cancer institute then, though not directly involved with its prostate cancer screening study. But he saw the reactions.

Some urologists said the study was unethical, because some people would not be screened, and demanded it be shut down, he said. One group of black urologists encouraged black men not to participate because blacks have a greater risk of prostate cancer and it seemed obvious they should be screened.

Some thought that they would see fewer cancer deaths among the screened men as quickly as five years. But as the studies continued, it became clear that screening would not have a large, immediate effect — if it did, the studies would have been stopped and victory declared. Cancer researchers began turning to less rigorous sources of data, with some arguing that screening was preventing prostate cancer deaths and others arguing it was not.

In the United States, many men and their doctors have made up their minds — most men over age 50 have already been screened, and each year more than 180,000 receive a diagnosis of prostate cancer. In Europe, said Dr. Fritz H. Schröder of Erasmus University, the lead author of the European study, most men are not screened. “The mentality of Europeans is different,” he said, and screening is not so highly promoted.

The publication, of data from the two studies should change the discussion, said Dr. David Ransohoff, an internist and cancer epidemiologist at the University of North Carolina.

“This is not relying on modeling anymore,” Dr. Ransohoff said. “This is not some abstract, pointy-headed exercise. This is the real world and this is real data.”

Both studies will continue to follow the men. It remains possible that the United States study will eventually find that screening can reduce the prostate cancer death rate, researchers say, or that both studies will conclude that there is no real reduction.

In the meantime, Dr. Brawley said, “I certainly think there’s information here that’s food for thought.”

The benefits of prostate cancer screening, he said, are “modest at best and with a greater downside than any other cancer we screen for.”

Web Link

Mortality Results from a Randomized Prostate-Cancer Screening Trial (The New England Journal of Medicine)

Screening and Prostate-Cancer Mortality in a Randomized European Study (The New England Journal of Medicine)

Monday, January 12, 2009

Vitamins E and C in the Prevention of Prostate and Total Cancer in Men

Moral of the story: More results from the Physicians' Health Study: Vitamins E and C do not reduce the risk for developing prostate cancer or any other cancer (or cardiovascular disease, as you may remember from the last post).

Vitamins E and C in the Prevention of Prostate and Total Cancer in Men

The Physicians' Health Study II Randomized Controlled Trial

J. Michael Gaziano, MD, MPH; Robert J. Glynn, ScD; William G. Christen, ScD; Tobias Kurth, MD, ScD; Charlene Belanger, MA; Jean MacFadyen, BA; Vadim Bubes, PhD; JoAnn E. Manson, MD, DrPH; Howard D. Sesso, ScD, MPH; Julie E. Buring, ScD

JAMA. 2009;301(1):52-62. Published online December 9, 2008 (doi:10.1001/jama.2008.862).

ABSTRACT


Context Many individuals take vitamins in the hopes of preventing chronic diseases such as cancer, and vitamins E and C are among the most common individual supplements. A large-scale randomized trial suggested that vitamin E may reduce risk of prostate cancer; however, few trials have been powered to address this relationship. No previous trial in men at usual risk has examined vitamin C alone in the prevention of cancer.

Objective To evaluate whether long-term vitamin E or C supplementation decreases risk of prostate and total cancer events among men.

Design, Setting, and Participants The Physicians' Health Study II is a randomized, double-blind, placebo-controlled factorial trial of vitamins E and C that began in 1997 and continued until its scheduled completion on August 31, 2007. A total of 14 641 male physicians in the United States initially aged 50 years or older, including 1307 men with a history of prior cancer at randomization, were enrolled.

Intervention Individual supplements of 400 IU of vitamin E every other day and 500 mg of vitamin C daily.

Main Outcome Measures Prostate and total cancer.

Results During a mean follow-up of 8.0 years, there were 1008 confirmed incident cases of prostate cancer and 1943 total cancers. Compared with placebo, vitamin E had no effect on the incidence of prostate cancer (active and placebo vitamin E groups, 9.1 and 9.5 events per 1000 person-years; hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.85-1.09; P = .58) or total cancer (active and placebo vitamin E groups, 17.8 and 17.3 cases per 1000 person-years; HR, 1.04; 95% CI, 0.95-1.13; P = .41). There was also no significant effect of vitamin C on total cancer (active and placebo vitamin C groups, 17.6 and 17.5 events per 1000 person-years; HR, 1.01; 95% CI, 0.92-1.10; P = .86) or prostate cancer (active and placebo vitamin C groups, 9.4 and 9.2 cases per 1000 person-years; HR, 1.02; 95% CI, 0.90-1.15; P = .80). Neither vitamin E nor vitamin C had a significant effect on colorectal, lung, or other site-specific cancers. Adjustment for adherence and exclusion of the first 4 or 6 years of follow-up did not alter the results. Stratification by various cancer risk factors demonstrated no significant modification of the effect of vitamin E on prostate cancer risk or either agent on total cancer risk.

Conclusions In this large, long-term trial of male physicians, neither vitamin E nor C supplementation reduced the risk of prostate or total cancer. These data provide no support for the use of these supplements for the prevention of cancer in middle-aged and older men.

Trial Registration clinicaltrials.gov Identifier: NCT00270647


Friday, January 9, 2009

Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate.

Moral of the Story: Broccoli is just plain good for you. The first in the broccoli series, this article explains how broccoli consumption can distrupt oncogenic pathways in your prostate via genetic mechanisms. Basically, you eat broccoli, you have a certain gene, you dont get prostate cancer


Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate.

Traka M, Gasper AV, Melchini A, Bacon JR, Needs PW, Frost V, Chantry A, Jones AM, Ortori CA, Barrett DA, Ball RY, Mills RD, Mithen RF.
Phytochemicals and Health Programme, Institute of Food Research, Norwich Research Park, Norwich, United Kingdom.

BACKGROUND: Epidemiological studies suggest that people who consume more than one portion of cruciferous vegetables per week are at lower risk of both the incidence of prostate cancer and of developing aggressive prostate cancer but there is little understanding of the underlying mechanisms. In this study, we quantify and interpret changes in global gene expression patterns in the human prostate gland before, during and after a 12 month broccoli-rich diet.
METHODS AND FINDINGS: Volunteers were randomly assigned to either a broccoli-rich or a pea-rich diet. After six months there were no differences in gene expression between glutathione S-transferase mu 1 (GSTM1) positive and null individuals on the pea-rich diet but significant differences between GSTM1 genotypes on the broccoli-rich diet, associated with transforming growth factor beta 1 (TGFbeta1) and epidermal growth factor (EGF) signalling pathways. Comparison of biopsies obtained pre and post intervention revealed more changes in gene expression occurred in individuals on a broccoli-rich diet than in those on a pea-rich diet. While there were changes in androgen signalling, regardless of diet, men on the broccoli diet had additional changes to mRNA processing, and TGFbeta1, EGF and insulin signalling. We also provide evidence that sulforaphane (the isothiocyanate derived from 4-methylsuphinylbutyl glucosinolate that accumulates in broccoli) chemically interacts with TGFbeta1, EGF and insulin peptides to form thioureas, and enhances TGFbeta1/Smad-mediated transcription.
CONCLUSIONS: These findings suggest that consuming broccoli interacts with GSTM1 genotype to result in complex changes to signalling pathways associated with inflammation and carcinogenesis in the prostate. We propose that these changes may be mediated through the chemical interaction of isothiocyanates with signalling peptides in the plasma. This study provides, for the first time, experimental evidence obtained in humans to support observational studies that diets rich in cruciferous vegetables may reduce the risk of prostate cancer and other chronic disease.
TRIAL REGISTRATION: ClinicalTrials.gov NCT00535977.